首页> 外文期刊>Histology and histopathology >Mesenchymal stem cells in connective tissue engineering and regenerative medicine: Applications in cartilage repair and osteoarthritis therapy
【24h】

Mesenchymal stem cells in connective tissue engineering and regenerative medicine: Applications in cartilage repair and osteoarthritis therapy

机译:间充质干细胞在结缔组织工程和再生医学中的应用:在软骨修复和骨关节炎治疗中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Defects of load-bearing connective tissues such as articular cartilage, often result from trauma, degenerative or age-related disease. Osteoarthritis (OA) presents a major clinical challenge to clinicians due to the limited inherent repair capacity of articular cartilage. Articular cartilage defects are increasingly common among the elderly population causing pain, reduced joint function and significant disability among affected patients. The poor capacity for self-repair of chondral defects has resulted in the development of a large variety of treatment approaches including Autologous Chondrocyte Transplantation (ACT), microfracture and mosaicplasty methods. In ACT, a cartilage biopsy is taken from the patient and articular chondrocytes are isolated. The cells are then expanded after several passages in vitro and used to fill the cartilage defect. Since its introduction, ACT has become a widely applied surgical method with good to excellent clinical outcomes. More recently, classical ACT has been combined with tissue engineering and implantable scaffolds for improved results. However, there are still major problems associated with the ACT technique which relate mainly to chondrocyte de-differentiation during the expansion phase in monolayer culture and the poor integration of the implants into the surrounding cartilage tissue. Novel approaches using mesenchymal stem cells (MSCs) as an alternative cell source to patient derived chondrocytes are currently on trial. MSCs have shown significant potential for chondrogenesis in animal models. This review article discusses the potential of MSCs in tissue engineering and regenerative medicineand highlights their potential for cartilage repair and cell-based therapies for osteoarthritis and a range of related osteoarticular disorders.
机译:承重结缔组织的缺损(例如关节软骨)通常是由外伤,退行性疾病或与年龄有关的疾病引起的。由于关节软骨固有的修复能力有限,骨关节炎(OA)对临床医生提出了重大的临床挑战。关节软骨缺损在老年人口中越来越普遍,导致受影响患者的疼痛,关节功能下降和严重残疾。软骨缺损的自我修复能力差,导致发展了多种治疗方法,包括自体软骨细胞移植(ACT),微骨折和镶嵌成形术。在ACT中,从患者身上取软骨活检,并分离关节软骨细胞。然后在体外传代数次后,将细胞扩增,并用于填充软骨缺损。自从问世以来,ACT已成为具有良好到极好的临床效果的广泛应用的手术方法。最近,经典ACT与组织工程和可植入支架相结合,以改善结果。但是,仍然存在与ACT技术相关的主要问题,这些问题主要与单层培养的扩张阶段的软骨细胞去分化以及植入物与周围软骨组织的整合不良有关。目前正在试验使用间充质干细胞(MSCs)作为源自患者的软骨细胞的替代细胞来源的新方法。 MSC已经显示出在动物模型中软骨形成的巨大潜力。这篇综述文章讨论了MSC在组织工程和再生医学中的潜力,并着重介绍了它们在软骨修复和基于细胞的骨关节炎和一系列相关骨关节疾病的细胞治疗中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号